US Edition
Published • loading... • Updated
Grail CEO Steps Down After Trial Setback
Summary by STAT
2 Articles
2 Articles
Grail CEO steps down after trial setback
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Cancer researchers have discovered that a notorious oncogene may occasionally wind up exposed on the outside of tumor cells, hinting at a surprising new immunotherapy target. Meanwhile, Trump continues to win the messaging war on drug pricing, and biotech’s social circles get awkward again with an Epstein-linked investor’s …
·Boston, United States
Read Full ArticleCoverage Details
Total News Sources2
Leaning Left0Leaning Right0Center2Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
